Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar 12;130(10):2959-61.
doi: 10.1021/ja709993p. Epub 2008 Feb 15.

Neuroactive chondroitin sulfate glycomimetics

Affiliations

Neuroactive chondroitin sulfate glycomimetics

Manish Rawat et al. J Am Chem Soc. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of (A) natural CS and (B) CS glycopolymers. Grey and white circles represent the monosaccharide subunits, red circles represent sulfation.
Figure 2
Figure 2
CS-E glycopolymers inhibit the outgrowth of hippocampal neurons. (A) Immunofluorescence images of neurons 48 h after treatment with the indicated compound. A fixed glucuronic acid concentration of 0.5 μg/mL was used in each case to examine the effects of multivalency. The molar concentrations were 14.3 nM for the natural CS-E polysaccharide, 12.1 nM for the CS-E tetrasaccharide polymer, and 16.6–53.0 nM for the disaccharide polymers. See Supporting Information for details. (B) Statistical analysis of neurite length. Error bars represent SEM from three separate experiments. P values are relative to the untreated neurons. See Supporting Information for conditions.
Figure 3
Figure 3
Comparison of the inhibitory potencies of CS glycopolymer 16 and the natural polysaccharide at various concentrations. IC50 values are based on the molar concentration of compound required to inhibit neurite outgrowth by 50% relative to untreated neurons. See Supporting Information for details.
Scheme 1
Scheme 1. Synthesis of the Disaccharide Monomera
a Conditions: (a) TMSOTf, CH2Cl2, −20 °C, 69%. (b) HF·pyr, THF/pyr, 25 °C, 95%. (c) AIBN, Bu3SnH, benzene, 50 °C, 92%. (d) DDQ, CH3CN/H2O, 25 °C, 89%. (e) SO3·TMA, DMF, 80 °C, 85%. (f) (i) HF·pyr, THF/pyr, 25 °C; (ii) LiOH, H2O2, then NaOH, MeOH, 25 °C, 89% (two steps).
Scheme 2
Scheme 2. Synthesis of Protected CS Glycopolymers a
a Conditions: (a) 8, 1:5 MeOH/(CH2Cl)2, 55 °C, 24 h. (b) TMSOTf, 4, CH2Cl2, −20 °C, 45%. (c) AIBN, Bu3SnH, benzene, 50 °C, 89%. (d) DDQ, CH3CN/H2O, 25 °C. (e) SO3·TMA, DMF, 80 °C, 71% (two steps).
Scheme 3
Scheme 3. CS Glycomimetics a
a Conditions: (a) (i) HF·pyr, THF/pyr, 25 °C; (ii) LiOH, H2O2, then NaOH, MeOH, 25 °C, 87–97% (two steps).

References

    1. Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. Nature. 2002;416:636–640. - PubMed
    2. Galtrey CM, Fawcett JW. Brain Res Rev. 2007;54:1–18. - PubMed
    3. Gama CI, Hsieh-Wilson LC. Curr Opin Chem Biol. 2005;9:609–619. - PubMed
    4. Mizuguchi S, Uyama T, Kitagawa H, Nomura KH, Dejima K, Gengyo-Ando K, Mitani S, Sugahara K, Nomura K. Nature. 2003;423:443–448. - PubMed
    5. Taylor KR, Gallo RL. FASEB J. 2006;20:9–22. - PubMed
    1. Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K. J Biol Chem. 2002;277:43707–43716. - PubMed
    2. Desaire H, Sirich TL, Leary JA. Anal Chem. 2001;73:3513–3520. - PubMed
    3. Li F, Shetty AK, Sugahara K. J Biol Chem. 2007;282:2956–2966. - PubMed
    4. Shipp EL, Hsieh-Wilson LC. Chem Biol. 2007;14:195–208. - PubMed
    1. Tully SE, Rawat M, Hsieh-Wilson LC. J Am Chem Soc. 2006;128:7740–7741. - PubMed
    2. Gama CI, Tully SE, Sotogaku N, Clark PM, Rawat M, Vaidehi N, Goddard WA, III, Nishi A, Hsieh-Wilson LC. Nat Chem Biol. 2006;2:467–473. - PubMed
    1. Tully SE, Mabon R, Gama CI, Tsai SM, Liu X, Hsieh-Wilson LC. J Am Chem Soc. 2004;126:7736–7737. - PubMed
    1. Bao X, Muramatsu T, Sugahara K. J Biol Chem. 2005;280:35318–35328. - PubMed
    2. Mohammadi M, Olsen SK, Goetz R. Curr Opin Struct Biol. 2005;15:506–516. - PubMed

Publication types

MeSH terms